Cancer Genetics and Epigenetics, 2025, Vol.13, No.6, 287-299 http://medscipublisher.com/index.php/cge 297 ctDNA can sensitively and in real time reflect tumor changes and is rapidly becoming a core technology for precise treatment of colorectal cancer. The application of it in postoperative monitoring, risk assessment and treatment guidance marks a shift in patient care towards being more targeted and effective. Although there are still some issues at present, such as the need for unified standards for detection methods and further verification in different clinical scenarios, more and more evidence indicates that ctDNA, as a non-invasive dynamic tool, is worthy of being incorporated into the routine diagnosis and treatment process for monitoring the condition and guiding treatment decisions. As research deepens and clinical guidelines are gradually improved, ctDNA is bound to play an increasingly important role in improving the prognosis and quality of life of patients with colorectal cancer. Acknowledgments The authors extend sincere thanks to MedSci Publisher for his feedback on the manuscript. Conflict of Interest Disclosure The authors affirm that this research was conducted without any commercial or financial relationships that could be construed as a potential conflict of interest. References Abidoye O., Ahn D., Borad M., Wu C., Bekaii-Saab T., Chakrabarti S., and Sonbol M., 2025, Circulating tumor DNA testing for minimal residual disease and its application in colorectal cancer, Cells, 14(3): 161. https://doi.org/10.3390/cells14030161 Andersen L., Kisistók J., Henriksen T., Bramsen J., Reinert T., Øgaard N., Mattesen T., Birkbak N., and Andersen C., 2024, Exploring the biology of ctDNA release in colorectal cancer, European Journal of Cancer, 207: 114186. https://doi.org/10.1016/j.ejca.2024.114186 Burley N., Lee Y., Liu L., Gangi A., Nasseri Y., Atkins K., Zaghiyan K., Murrell Z., Osipov A., Hendifar A., Hitchins M., and Gong J., 2024, ctDNA-guided adjuvant immunotherapy in colorectal cancer, Immunotherapy, 16(20-22): 1197-1202. https://doi.org/10.1080/1750743x.2024.2430941 Chen H., An Y., Wang C., and Zhou J., 2025, Circulating tumor DNA in colorectal cancer: biology methods and applications, Discover Oncology, 16(1): 439. https://doi.org/10.1007/s12672-025-02220-z Chidharla A., Rapoport E., Agarwal K., Madala S., Linares B., Sun W., Chakrabarti S., and Kasi A., 2023, Circulating tumor DNA as a minimal residual disease assessment and recurrence risk in patients undergoing curative-intent resection with or without adjuvant chemotherapy in colorectal cancer: a systematic review and meta-analysis, International Journal of Molecular Sciences, 24(12): 10230. https://doi.org/10.3390/ijms241210230 Chung J., Xiao S., Gao Y., and Soung Y., 2024, Recent technologies towards diagnostic and therapeutic applications of circulating nucleic acids in colorectal cancers, International Journal of Molecular Sciences, 25(16): 8703. https://doi.org/10.3390/ijms25168703 Gao Z., Huang D., Chen H., Yang Y., An K., Ding C., Yuan Z., Zhai Z., Niu P., Gao Q., Cai J., Zeng Q., Wang Y., Hong Y., Rong W., Huang W., Lei F., Wang X., Chen S., Zhao X., Bai Y., and Gu J., 2023, Development and validation of postoperative circulating tumor DNA combined with clinicopathological risk factors for recurrence prediction in patients with stage I-III colorectal cancer, Journal of Translational Medicine, 21(1): 63. https://doi.org/10.1186/s12967-023-03884-3 Gu N., Waters-Banker C., Carter G., Badgley D., Vidisheva A., Palomares M., Johnson H., and Smith N., 2025, Abstract 1933: Improving detection of colorectal cancer recurrence using serial ctDNA measurements: a systematic literature review, Cancer Research, 85(8_Supplement_1): 1933. https://doi.org/10.1158/1538-7445.am2025-1933 Hashimoto T., Kobayashi S., Oki E., Nakamura Y., Kinoshita T., Nonomura N., Matsuura K., Watari H., Gotohda N., Fujita T., Iwata H., Namikawa K., Sakashita S., Koga Y., Fujisawa T., Bando H., Yoshino T., Jasper J., Taber K., and Muzzey D., 2025, Ultra-sensitive pan-cancer molecular residual disease assessment using whole-genome sequencing-based personalized ctDNA panel: initial results from the MONSTAR-SCREEN-3 project, Journal of Clinical Oncology, 43(16_suppl): 3007. https://doi.org/10.1200/jco.2025.43.16_suppl.3007 Hashimoto T., Nakamura Y., Young G., Palomares M., Subramaniam S., Hall D., Frederick J., Oki E., Kotani D., Mishima S., Watanabe J., Akazawa N., Kataoka K., Bando H., Kato T., Costa G., Mazloom A., Garces J., Baehner F., and Yoshino T., 2025, The association of ctDNA with recurrence in patients with stage II-IV colorectal cancer: the β-CORRECT study, Journal of Clinical Oncology, 43(16_suppl): 3590. https://doi.org/10.1200/jco.2025.43.16_suppl.3590 Hoang T., Choi M., Oh J., and Kim J., 2025, Utility of circulating tumor DNA to detect minimal residual disease in colorectal cancer: a systematic review and network meta‐analysis, International Journal of Cancer, 157: 722-740. Holz A., Paul B., Zapf A., Pantel K., and Joosse S., 2025, Circulating tumor DNA as prognostic marker in patients with metastatic colorectal cancer undergoing systemic therapy: a systematic review and meta-analysis, Cancer Treatment Reviews, 139: 102999.
RkJQdWJsaXNoZXIy MjQ4ODYzNA==